

COMPARISON OF THE WHO ATC CLASSIFICATION & EphMRA/Intellus Worldwide ANATOMICAL CLASSIFICATION

November 2020

EphMRA

Intellus
Worldwide 

Comparison of the WHO ATC Classification and EphMRA / Intellus Worldwide Anatomical Classification

The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. EphMRA and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence.

In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified.

WHO mainly classifies **substances** according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product).

EphMRA classifies **products**, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only.

The purposes of classification are also different:

The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring.

This classification is recommended by the WHO for use in international drug utilisation research.

The EphMRA/Intellus Worldwide classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems.

The aim of harmonisation is to reach a "full" agreement of all mono substances in a given class as listed in the WHO ATC Index, mainly at third level: whenever this is not possible, or harmonisation of third level is too difficult or makes no sense (e.g. C2, R3), the second level will be taken as the reference class.

Harmonisation is not a simple adaptation of two systems; harmonisation is clearly an improvement of the existing systems.

In view of the increasing use of the WHO classification by national and international authorities and institutions with different objectives, it is opportune to have a harmonised classification.

The main benefit is that all parties involved in a given topic, use the same definitions, same substances, and therefore the discussions are easier. In line with the harmonisation procedure of WHO/EphMRA, this booklet has been prepared to facilitate cross-comparison. The comparison has been based on the WHO guidelines. Whenever possible, we have checked all molecules included in the current WHO/ATC Index with the EphMRA coding. We have tried to simplify the document and for this reason and according to the pre-agreed mandate of harmonisation, only the 3rd level has been used as a point of reference.

However, in some cases (e.g. A2B1 antiulcer and group L) we have also mentioned the 4th levels in our comparison.

Where the two groups are similar, on the EphMRA side only the code and the title has been added.

Where a difference exists, this has been notified using the following symbols:

- ❖ This class/code does not exist (e.g. A03B)
- ⤴ The heading or the content of this class may be different (e.g. N5C).
- ▶ These substances are classified in a different class.
- + This class is covered by more than one EphMRA/Intellus Worldwide or WHO class

A lot of discrepancies concern rather obsolete products for which there is no need for harmonisation (e.g. products withdrawn from the market, sales of minor importance).

We hope this booklet will improve both the use and understanding of the two systems, in particular for those companies in which the two systems are used by different departments (medical and marketing).

The Committee has tried to make a comprehensive comparison of both systems, but cannot guarantee a 100% level of accuracy. For complete guidelines on the WHO ATC systems refer to "Guidelines for ATC classification" and for the EphMRA/Intellus Worldwide Anatomical classification system refer to "EphMRA / Intellus Worldwide classification".

To obtain the guidelines please contact:

Norwegian Institute of Public Health
WHO Collaborating Centre
for Drug Statistics Methodology
P.O. Box 222 Skøyen,
N-0213 Oslo
Norway
email: whocc@fhi.no
web: www.whocc.no

Bernadette Rogers
General Manager
c/o Streicher & Brotschin treuhand
Gartenstrasse 101
4052 Basel
Switzerland
generalmanager@ephmra.org

Carol Reilly
Executive Director, Intellus Worldwide
1758 Allentown Road, Box 209
Lansdale, PA 19446
USA
Telephone: [1] 215 855 5255
Fax: [1] 215 855 5622
Email: carol@intellus.org

WHO (Substance Based)

A	ALIMENTARY TRACT AND METABOLISM
A01	STOMATOLOGICAL PREPARATIONS
A01A	STOMATOLOGICAL PREPARATIONS
	➤ Preparations for the treatment of throat infections (lozenges for common cold conditions) are classified in R02 - Throat preparations.
	➤ Cevimeline is classified in N7A.
❖	
A02	DRUGS FOR ACID RELATED DISORDERS
A02A	ANTACIDS
	➤ Plain antitflatulents, see A02BX
A02B	DRUGS FOR PEPTIC ULCER and GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02B A	H2-receptor antagonists
A02B B	Prostaglandins
A02B C	Proton pump inhibitors
A02B D	Combinations for eradication of Helicobacter pylori
A02B X	Other drugs for peptic ulcer and gastro-oesophageal disease (GORD)
	➤ Chlorbenzoxamine is classified in A03A.

EphMRA (Product Based)

A	ALIMENTARY TRACT AND METABOLISM
A1	STOMATOLOGICALS, MOUTH PREPARATIONS, MEDICINAL DENTIFRICES ETC.
A1A	STOMATOLOGICALS
	➤ Products indicated for both the posterior part of the mouth and throat infections are classified in R2A or A1A depending on their main indication.
	➤ Cevimeline is classified here.
A1B	MOUTH ANTIFUNGALS
A2	ANTACIDS, ANTIFLATULENTS AND ANTI-ULCERANTS
A2A	ANTACIDS, ANTIFLATULENTS, CARMINATIVES
	➤ Plain antitflatulents are classified in this group.
A2B	ANTIULCERANTS
A2B1	H2 antagonists
A2B3	Prostaglandin antiulcerants
A2B2	Proton pump inhibitors
	❖ Combinations for eradication of Helicobacter pylori are classified in A2B according to the antiulcerant.
A2B4	Bismuth antiulcerants
	+
A2B9	All other antiulcerants
	➤ Chlorbenzoxamine is classified here.

WHO (Substance Based)

EphMRA (Product Based)

A02X OTHER DRUGS FOR ACID RELATED DISORDERS

A2X OTHER STOMACH DISORDER PRODUCTS

A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS

A3 FUNCTIONAL GASTRO-INTESTINAL DISORDER DRUGS

A03A DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS

A3A PLAIN ANTISPASMODICS AND ANTICHOLINERGICS

➤ Chlorbenzoxamine is classified here.

➤ Chlorbenzoxamine is classified in A2B9.

➤ Trimebutine is classified here.

➤ Trimebutine is classified in A3F.

➤ Alosetron is classified here (A03A E).

➤ Alosetron is classified in A3G.

+

A03B BELLADONNA AND DERIVATIVES, PLAIN

❖

A03C ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS

A3C ANTISPASMODIC/ATARACTIC COMBINATIONS

A03D ANTISPASMODICS IN COMBINATION WITH ANALGESICS

A3D ANTISPASMODIC/ANALGESIC COMBINATIONS

➤ Combinations with both psycholeptics and analgesics are classified in A03E A.

➤ Combination of both ataractic and analgesic are classified here.

A03E ANTISPASMODICS AND ANTICHOLINERGICS IN COMBINATION WITH OTHER DRUGS

A03E A Antispasmodics, psycholeptics and analgesics in combination

➤ Antispasmodics in combination with psycholeptics, analgesics and other agents are classified in this group.

➤ Combinations of both ataractics and analgesics are classified in A3D.

A03E D Antispasmodics in combination with other drugs

A3E

ANTISPASMODICS COMBINED WITH OTHER PRODUCTS

WHO (Substance Based)

A03F PROPULSIVES
➤ Trimebutine is classified in A03A.



- Alosetron is classified in A03A E.
- Tegaserod is classified in A06A X.
- Linaclotide is classified in A06A X.
- Lubiprostone is classified in A06A X.
- Plecanatide is classified in A06A X.

A04 ANTIEMETICS AND ANTINAUSEANTS
A04A ANTIEMETICS AND ANTINAUSEANTS
➤ Antihistamines are classified in R06A.

A05 BILE AND LIVER THERAPY
A05A BILE THERAPY

EphMRA (Product Based)

A3F GASTROPROKINETICS
➤ Trimebutine is classified here.

A3G GASTRO-INTESTINAL SENSORIMOTOR MODULATORS
➤ Alosetron is classified here.
➤ Tegaserod is classified here.
➤ Linaclotide is classified here when indicated in IBS-c (290mcg), but in A6A when indicated in chronic constipation (145mcg); linaclotide for IBS-c and chronic constipation is classified here.
➤ Lubiprostone is classified here when indicated in IBS-c (8mcg), but in A6A when indicated in chronic constipation (24mcg).
➤ Plecanatide when indicated for both chronic constipation and IBS-c is classified here.
➤ Other drugs for constipation, including laxatives, are classified in A6A.

A4 ANTIEMETICS AND ANTINAUSEANTS
A4A ANTIEMETICS AND ANTINAUSEANTS
➤ Antihistamines used in motion sickness are classified here.

A5 CHOLAGOGUES AND HEPATIC PROTECTORS
A5A BILE THERAPY AND CHOLAGOGUES

WHO (Substance Based)

A05B LIVER THERAPY, LIPOTROPICS

A05C DRUGS FOR BILE THERAPY AND LIPOTROPICS IN COMBINATION

A06 DRUGS FOR CONSTIPATION
A06A DRUGS FOR CONSTIPATION

- Tegaserod is classified here.
- Linaclotide is classified here.
- Lubiprostone is classified here.
- Plecanatide is here

A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY / ANTIINFECTIVE AGENTS
A07A INTESTINAL ANTIINFECTIVES

A07B INTESTINAL ADSORBENTS

- Ceratonia is classified in A07X.

EphMRA (Product Based)

A5B HEPATIC PROTECTORS, LIPOTROPICS

A5C CHOLAGOGUE/LIPOTROPIC COMBINATIONS

A6 DRUGS FOR CONSTIPATION AND BOWEL CLEANSERS
A6A DRUGS FOR CONSTIPATION

- Tegaserod is classified in A3G.
- Linaclotide is classified here when indicated in chronic constipation (145mcg) but in A3G when indicated in IBS-c (290mcg).
- Lubiprostone is classified here when indicated in chronic constipation (24mcg) but in A3G when indicated in IBS-c (8mcg).
- Plecanatide is classified here when indicated for chronic constipation, but in A3G when also indicated for irritable bowel syndrome—constipation.

+

A6B BOWEL CLEANSERS

A7 INTESTINAL DISORDER PRODUCTS
A7A INTESTINAL ANTIINFECTIVES

A7B INTESTINAL ABSORBANT ANTIDIARRHOEALS

- Ceratonia is classified here.

WHO (Substance Based)

A07C	ELECTROLYTES WITH CARBOHYDRATES
A07D	ANTIPROPULSIVES
A07E	INTESTINAL ANTIINFLAMMATORY AGENTS ➤ Vedolizumab and darvadstrocel are classified in L04A.

A07F ANTIDIARRHEAL MICROORGANISMS

A07X OTHER ANTIDIARRHEALS
➤ Ceratonia is classified here.
➤ Telotristat is classified in A16A.

A08 ANTI OBESITY PREPARATIONS, EXCL. DIET PRODUCTS

A08A ANTI OBESITY PREPARATIONS, EXCL. DIET PRODUCTS
➤ Amphetamine is classified in N06B.
➤ Liraglutide is classified in A10B.

A09 DIGESTIVES, INCL. ENZYMES

A09A DIGESTIVES, INCL. ENZYMES
➤ Bromelains is classified in B06A A.

EphMRA (Product Based)

A7G ORAL ELECTROLYTE REPLACERS

A7H MOTILITY INHIBITORS

A7E INFLAMMATORY BOWEL DISORDER PRODUCTS
➤ Vedolizumab and darvadstrocel are classified here.

A7F ANTIDIARRHOEAL MICRO-ORGANISMS

A7X INTESTINAL DISORDER PRODUCTS, OTHER
➤ Ceratonia is classified in A7B.
➤ Telotristat is classified here.

A8 ANTI OBESITY PREPARATIONS, EXCL. DIETETICS

A8A ANTI OBESITY PREPARATIONS, EXCL. DIETETICS
➤ Amphetamine, when indicated as antiobesity product, is classified here.
➤ Liraglutide for weight management only is classified here.

A9 DIGESTIVES, INCLUDING ENZYMES

A9A DIGESTIVES, INCLUDING ENZYME
➤ Bromelains is classified here or, D3 and V3H depending on indications.

WHO (Substance Based)

- Chymotrypsin and trypsin are classified in B06A A when used as haematological enzymes.

EphMRA (Product Based)

- Chymotrypsin is classified here or in C5B, D3A, M2A and V3H depending on indications.
- Trypsin is classified here or in V3H and V3X depending on indications.

A10 DRUGS USED IN DIABETES

A10A INSULINS and ANALOGUES

A10 DRUGS USED IN DIABETES

A10C HUMAN INSULINS and ANALOGUES

+

A10D ANIMAL INSULINS

A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS

- Guar gum is classified here.

A10H SULPHONYLUREA ANTIDIABETICS

A10J BIGUANIDE ANTIDIABETICS

A10K GLITAZONE ANTIDIABETICS

A10L ALPHA-GLUCOSIDASE INHIBITOR ANTIDIABETICS

A10M GLINIDE ANTIDIABETICS

A10N DPP-IV INHIBITOR ANTIDIABETICS

A10P SGLT2 INHIBITOR ANTIDIABETICS

A10S GLP-1 AGONIST ANTIDIABETICS

- Liraglutide for weight management only is classified in A8A.

A10X OTHER DRUGS USED IN DIABETES

Includes aldose reductase inhibitors.

A10X OTHER DRUGS USED IN DIABETES

A10X1 Antidiabetic multitherapy combination products.

WHO (Substance Based)

- Guar gum is classified in A10B.
- Thioctic acid is classified in A16A.
- Combinations of DPP-IV inhibitors with statins are classified in A10B H.

EphMRA (Product Based)

Includes combinations of antidiabetics with cardiovascular drugs where the aim is to treat both the diabetes and the cardiovascular condition. Also includes combinations of antidiabetics with anti-obesity drugs where the aim is to treat both the diabetes and the obesity.

A10X9

Other drugs used in diabetes.

- Guar gum is classified here.
- Thioctic acid is classified here or A16A.

A11 VITAMINS
Vitamin B₁₂ is classified in B03.

A11 VITAMINS
➤ Vitamin B₁₂ is classified in A11F, which is a code only used in the EphMRA/Intellus Worldwide system.
➤ High-dose single-ingredient biotin indicated for multiple sclerosis only is classified in N7A.

A12 MINERAL SUPPLEMENTS

A12 MINERAL SUPPLEMENTS

A12A CALCIUM
Products indicated for hyperphosphatemia only are classified in V03AE.
Other calcium supplement products are classified here.

A12A CALCIUM PRODUCTS
➤ Products indicated for hyperphosphatemia and calcium deficiency are classified in V03G2.

A12B POTASSIUM

A12B POTASSIUM PRODUCTS

A12C OTHER MINERAL SUPPLEMENTS

A12C OTHER MINERAL SUPPLEMENTS

WHO (Substance Based)

A13 TONICS
A13A TONICS

A14 ANABOLIC AGENTS FOR SYSTEMIC USE
A14A ANABOLIC STEROIDS

A14B OTHER ANABOLIC AGENTS

A15 APPETITE STIMULANTS
➤ Cyproheptadine is classified in R06A.
➤ Pizotifen is classified in N02C.

A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
➤ Includes levocarnitine, ademetonine, thioctic acid.
➤ Zinc acetate is classified here.
➤ Telotristat is classified here.
➤ Cerliponase alfa is classified here

EphMRA (Product Based)

A13 TONICS
A13A TONICS

The large number of products in this class make it impossible to fully state that they are equal.

A14 ANABOLICS, SYSTEMIC
A14A ANABOLIC HORMONES, SYSTEMIC

A14B OTHER ANABOLIC AGENTS, SYSTEMIC

A15 APPETITE STIMULANTS
➤ Cyproheptadine when indicated as appetite stimulant, is classified here, otherwise it is classified in R6A.
➤ Pizotifen is classified here; when indicated for migraine, is classified in N2C.

A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
➤ Levocarnitine is classified here but when indicated for ischaemic disorders, it is classified in C1X.
➤ Ademetonine is classified in N6A.
➤ Thioctic acid is classified here or in A10X.
➤ Combinations of diabetes and cardiovascular products are classified in A10X1.

WHO (Substance Based)

B	BLOOD AND BLOOD FORMING ORGANS
B01	ANTITHROMBOTIC AGENTS
B01A	ANTITHROMBOTIC AGENTS
↻	
B01A A	Vitamin K antagonists
B01A B	Heparin group
	➤ Antithrombin III is classified here.
	➤ Danaparoid is classified here.
B01A C	Platelet aggregation inhibitors excl. heparin
	➤ Dipyramidole is classified here.
	➤ Defibrotide is classified in B01A X.
	➤ Prostacyclin agonists (e.g. iloprost, selexipag, treprostinil, and epoprostenol) are classified here.
B01A D	Enzymes
↻	
	➤ Protein C and activated Protein C are classified here.

EphMRA (Product Based)

- Zinc acetate is classified in V3E when indicated for Wilson's disease.
- Telotristat is classified in A7X
- Cerliponase alfa is classified in N7X

B	BLOOD AND BLOOD FORMING ORGANS
B1	ANTITHROMBOTIC AGENTS
↻	
B1A	VITAMIN K ANTAGONISTS
B1B	HEPARINS
	➤ Antithrombin III is classified in B2C.
	➤ Danaparoid is classified in B1X.
B1C	PLATETLET AGGREGATION INHIBITORS
	➤ Dipyramidole is classified here; when indicated for coronary therapy it is classified in C1D.
	➤ Defibrotide is classified here.
	➤ Prostacyclin agonists (e.g. iloprost, selexipag, treprostinil) and indicated for pulmonary hypertension only are classified in C6B3.
	➤ Epoprostenol is classified in C6B3.
B1D	FIBRINOLYTICS
↻	
	➤ Protein C and activated Protein C are classified in B1X.

WHO (Substance Based)

- B01A E Direct thrombin inhibitors
 B01A F Direct factor Xa inhibitors
 B01A X Other antithrombotic agents
 ➤ Defibrotide is classified here.

B02 ANTIHEMORRHAGICS

- B02A ANTIFIBRINOLYTICS
 B02A A Amino acids
 B02A B Proteinase inhibitors
 ➤ Alfa 1 antitrypsin (alpha-1-proteinase inhibitor) is classified here.

B02B VITAMIN K AND OTHER HEMOSTATICS

- B02B A Vitamin K
 ➤ Protamin is classified in V03A.
 ➤ Idarucizumab and andexanet alfa are classified in V03A

B02B B Fibrinogen

B02B C Local hemostatics

B02B D Blood coagulation factors

- Emicizumab is classified in B02B X



- Eltrombopag, romiplostim, lusutrombopag, and avatrombopag are classified in B02B X.

EphMRA (Product Based)

- B1E DIRECT THROMBIN INHIBITORS
 B1F DIRECT FACTOR XA INHIBITORS
 B1X OTHER ANTITHROMBOTIC AGENTS
 ➤ Defibrotide is classified in B1C.

B2 BLOOD COAGULATION SYSTEM, OTHER PRODUCTS

- B2A ANTIFIBRINOLYTICS
 B2C PROTEINASE INHIBITORS
 ➤ Alpha-1-proteinase inhibitor (alfa 1 antitrypsin) is classified in R3X.

B2B ANTAGONISTS (ANTIDOTES TO ANTICOAGULANTS)

- B2B1 Vitamin K
 B2B2 Protamin sulphate
 B2B9 Antidotes to anticoagulants, other
 ➤ Idarucizumab and andexanet alfa are classified here.

B2F TISSUE SEALING PREPARATIONS

- Local haemostatics are classified in D3A

B2D BLOOD COAGULATION

- Emicizumab is classified here.

B2E THROMBOPOIETIN AGONISTS

- Eltrombopag, romiplostim, lusutrombopag, and avatrombopag are classified here.

WHO (Substance Based)

- B02B X Other systemic hemostatics
- ▶ Eltrombopag, romiplostim, lusutrombopag, and avatrombopag are classified here.
 - ▶ Emicizumab is classified here.

B03 ANTIANEMIC PREPARATIONS

- B03A IRON PREPARATIONS
- ▶ All plain iron preparations and all combination products containing more than 30 mg Fe per defined daily dose (DDD), are classified here, even if they contain multivitamins.

B03B VITAMIN B12 AND FOLIC ACID



B03B A Vitamin B12 (cyanocobalamin and analogues)

B03B B Folic acid and derivatives

- ▶ Folinic acid is classified in V03A.



B03X OTHER ANTIANEMIC PREPARATIONS



EphMRA (Product Based)

- B2G SYSTEMIC HAEMOSTATICS
- ▶ Eltrombopag, romiplostim, lusutrombopag, and avatrombopag are classified in B2E.
 - ▶ Parenteral conjugated oestrogens for control of uterine bleeding are classified here.
 - ▶ Emicizumab is classified in B2D.

B3 ANTI-ANAEMIC PREPARATIONS

- B3A HAEMATINICS, IRON & ALL COMBINATIONS
- ▶ Combinations of iron with multivitamins are classified in A11A.

B3B LIVER EXTRACTS AND COMBINATIONS WITH B12

A11F PLAIN VIT B12

B3X OTHER ANTI-ANAEMIC PRODUCTS, INCLUDING FOLIC ACID, FOLINIC ACID

- ▶ Folinic acid with more than one indication classified in V3D.

B3C ERYTHROPOIETIN PRODUCTS

B3D HIF-PH INHIBITORS

WHO (Substance Based)



B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS

B05A BLOOD AND RELATED PRODUCTS

B05A A Blood substitutes and plasma protein fractions

B05B I.V. SOLUTIONS

B05B A Solutions for parenteral nutrition



B05B B Solutions affecting the electrolyte balance

➤ Trometamol is classified in K4B.

B05B C Solutions producing osmotic diuresis

B05C IRRIGATING SOLUTIONS

B05D PERITONEAL DIALYTICS

B05X I.V. SOLUTION ADDITIVES

B05Z HEMODIALYTICS AND HEMOFILTRATES

B05Z A Hemodialytics, concentrates

B05Z B Hemofiltrates

EphMRA (Product Based)



K HOSPITAL SOLUTIONS



K3B PROTEIN SOLUTIONS



K2 PLASMA EXPANDERS

K1 INTRAVENOUS SOLUTIONS

K1F SOLUTIONS FOR OSMOTIC THERAPY

➤ Trometamol is classified here.

K5 IRRIGATING SOLUTIONS

K6B PERITONEAL DIALYSIS SOLUTIONS

K4 INJECTION SOLUTIONS/INFUSION ADDITIVES

K6A HAEMODIALYSIS SOLUTIONS

K6C HAEMOFILTRATION

WHO (Substance Based)

B06	OTHER HEMATOLOGICAL AGENTS
B06A	OTHER HEMATOLOGICAL AGENTS
B06A A	Enzymes ➤ Chymotrypsin and trypsin are classified here when used as haematological enzymes.
B06A B	Heme products ➤ Ruxolitinib is classified in L01X E.
B06A C	DRUGS USED IN HEREDITARY ANGIOEDEMA

C CARDIOVASCULAR SYSTEM

C01	CARDIAC THERAPY
C01A	CARDIAC GLYCOSIDES

C01B	ANTIARRHYTHMICS, CLASS I AND III ➤ Adenosine is classified in C01E. ➤ Mexiletine is classified here.
------	--

C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01C A	Adrenergic and dopaminergic agents ➤ Caffeine, plain is classified in N06B. ➤ Heptaminol is classified in C01D.

EphMRA (Product Based)

B6	ALL OTHER HAEMATOLOGICAL AGENTS
B6X	OTHER HAEMATOLOGICAL AGENTS
B6B	HYALURONIDASE
❖	➤ Ruxolitinib for cancer only is classified in L1H9.
B6D	HEREDITARY ANGIOEDEMA PRODUCTS

C CARDIOVASCULAR SYSTEM

C1	CARDIAC THERAPY
C1A	CARDIAC GLYCOSIDES AND COMBINATIONS

C1B	ANTI-ARRHYTHMICS ➤ Adenosine is classified here. ➤ Mexiletine for cardiac arrhythmias is classified here; when indicated for non-dystrophic myotonic disorders it is classified in M5X.
-----	---

C1C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES ➤ Caffeine, plain is classified here. ➤ Heptaminol is classified here.
+	

WHO (Substance Based)

- Dihydroergotamine is classified in N02C.
- Angiotensin II is classified in C01CX.

C01C E Phosphodiesterase Inhibitors



+

C01C X Other cardiac stimulants

- Angiotensin II is classified here.

C01D VASODILATORS USED IN CARDIAC DISEASES

C01D A Organic nitrates

- Amyl nitrite is classified in V03A.

C01D B Quinolone vasodilators

- Flosequinan is classified here.

C01D X Other Vasodilators used in cardiac diseases

- Prenylamine is classified here.
- Heptaminol is classified here.
- Serelaxin is classified here.
- Nesiritide is classified here.
- Dipyramidol is classified in B01A C.
- Trimetazidine is classified in C01E B.

EphMRA (Product Based)

- Dihydroergotamine is classified here and in N2C.
- Angiotensin II is classified here.

C1F POSITIVE INOTROPIC AGENTS

- Includes substances such as amrinone, milrinone, fenoximone, piroximone, xamoterol.
- Angiotensin II is classified in C1C.

C01D A Organic nitrates

C1E NITRITES AND NITRATES

- Amyl nitrite is classified here and V3A.

C01D B Quinolone vasodilators



- Flosequinan is classified in C1D.

C01D X Other Vasodilators used in cardiac diseases

C1D CORONARY THERAPY EXCL. CALCIUM ANTAGONISTS AND NITRITES

- Prenylamine is classified in C8A.
- Heptaminol is classified in C1C.
- Dipyramidol is classified here and in B1C.
- Nesiritide is classified in C1X.
- Trimetazidine is classified here.

WHO (Substance Based)

- Ivabradine is classified in C01E B.
- Flosequinan is classified in C01D B.

C01E	OTHER CARDIAC PREPARATIONS
	➤ Adenosine is classified here.
	➤ Levocarnitine is classified in A016.
	➤ Trimetazidine is classified here.
	➤ Ivabradine is classified here.
	➤ Nesiritide is classified in C01D X.
	➤ Tafamidis is classified in N07X.

EphMRA (Product Based)

- Ivabradine is classified here.
- Flosequinan is classified here.

C1X	ALL OTHER CARDIAC PREPARATIONS
	➤ Adenosine is classified in C1B.
	➤ Levocarnitine is classified in this group when indicated for ischaemic disorders (in A16 if for nutrition problems).
	➤ Ivabradine is classified in C1D.
	➤ Nesiritide is classified here.
	➤ Tafamidis for transthyretin amyloid cardiomyopathy only is classified here; otherwise it is classified in N7X.

C02	ANTIHYPERTENSIVES
	➤ Mebutamate is classified in N05B.
	➤ Terazosin is classified in G04C.
	➤ Bosentan, ambrisentan, macitentan, riociguat and sitaxentan are classified in C02KX.

C2	ANTIHYPERTENSIVES
	➤ Mebutamate is classified in C2A.
	➤ Terazosin is classified here and in G4C.
	➤ Bosentan, ambrisentan, macitentan, riociguat and sitaxentan are classified in C6B.
	➤ Indoramin for migraine is classified in N2C9.

C03	DIURETICS
	➤ Cicletanine is classified here.

C3	DIURETICS
	➤ Cicletanine is classified in C2A.

C04	PERIPHERAL VASODILATORS
C04A	PERIPHERAL VASODILATORS

C4	CEREBRAL AND PERIPHERAL VASOTHERAPEUTICS
C4A	CEREBRAL AND PERIPHERAL VASOTHERAPEUTICS

WHO (Substance Based)

- Cinnarizine and flunarizine are classified in N07C.
- Nimodipine is classified in C08.
- Citicoline is classified in N06B.
- Visnadine is classified here.

EphMRA (Product Based)

- Cinnarizine and flunarizine can be classified here and also in N2C and N7C depending on indications.
- Nimodipine is classified here.
- Citicoline is classified here.
- Visnadine is classified in C1D.

C05 VASOPROTECTIVES

C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE

C05B ANTIVARICOSE THERAPY

- Chymotrypsin is classified in B06A A when used as haematological enzymes.

C05C CAPILLARY STABILIZING AGENTS



- Bosentan, ambrisentan, macitentan, riociguat and sitaxentan are classified in C02K X.
- Sildenafil is classified in G04B E.
- Prostacyclin agonists (e.g. iloprost, selexipag, treprostinil epoprostenol) are classified in B01A C.

C5 ANTIVARICOSIS/ANTIHAEMORRHOIDAL PREPARATIONS

C5A TOPICAL ANTI-HAEMORRHOIDALS

C5B VARICOSE THERAPY, TOPICAL

- Chymotrypsin is classified here or in A9A, D3A, M2A and V3H depending on indications

C5C VARICOSE THERAPY, SYSTEMIC

C6 OTHER CARDIOVASCULAR PRODUCTS

C6B PULMONARY ARTERIAL HYPERTENSION (PAH) PRODUCTS

- Ambrisentan, bosentan, macitentan, riociguat and sitaxentan are classified here.
- PDE5 inhibitors indicated only for pulmonary arterial hypertension are classified here.
- Prostacyclin agonist PAH products (e.g. iloprost, selexipag, treprostinil) and indicated for pulmonary hypertension only are classified here.

WHO (Substance Based)

EphMRA (Product Based)

➤ Epoprostenol is classified here.

C6X

OTHER CARDIOVASCULAR PRODUCTS

C07 BETA BLOCKING AGENTS

C07A BETA BLOCKING AGENTS

C7 BETA BLOCKING AGENTS

C7A BETA BLOCKING AGENTS, PLAIN

C07B BETA BLOCKING AGENTS AND THIAZIDES

+

C07C BETA BLOCKING AGENTS AND OTHER DIURETICS

+

C07D BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS

+

C07E BETA BLOCKING AGENTS AND VASODILATORS

C7B BETA BLOCKING AGENTS, COMBINATIONS

C07F B Beta blocking agents and calcium channel blockers

C07F X Beta blocking agents, other combinations

C8B2 Calcium antagonist/beta blocker combinations

❖

C08 CALCIUM CHANNEL BLOCKERS

➤ Nimodipine is classified here.

➤ Prenylamine is classified in C01D X.

➤ Combinations with beta blockers are classified in C07F X.

C8 CALCIUM ANTAGONISTS

➤ Nimodipine is classified in C4A.

➤ Prenylamine is classified here.

➤ Combinations with beta blockers are classified in C8B2.

WHO (Substance Based)

C08C	SELECTIVE CCB WITH MAINLY VASCULAR EFFECT
+	▶ Combination of amlodipine + celecoxib is classified here.
C08D	SELECTIVE CCB WITH DIRECT CARDIAC EFFECTS
+	
C08E	NON-SELECTIVE CALCIUM CHANNEL BLOCKERS

C08G CALCIUM CHANNEL BLOCKERS AND DIURETICS



C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

C09A ACE INHIBITORS, PLAIN

C09B ACE INHIBITORS, COMBINATIONS

C09C ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN

C09D ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS

EphMRA (Product Based)

C8A CALCIUM ANTAGONISTS, PLAIN
▶ Combination of amlodipine + celecoxib is classified in C8B4.

C8B1 CALCIUM ANTAGONISTS COMBINATIONS WITH ANTIHYPERTENSIVES (C2) AND/OR DIURETICS

C8B2 CCB/BETABLOCKER COMBINATIONS

C8B3 CCB COMB. WITH OTHER DRUGS OF GROUP C, except C7-C10

C8B4 CCB COMBINATIONS WITH ALL OTHER DRUGS

▶ Combination of amlodipine + celecoxib is classified here.

C9 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

C9A ACE INHIBITORS, PLAIN

C9B ACE INHIBITORS, COMBINATIONS

C9C ANGIOTENSIN II ANTAGONISTS, PLAIN

C9D ANGIOTENSIN II ANTAGONISTS, COMBINATIONS

WHO (Substance Based)

C09X OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

C10 LIPID MODIFYING AGENTS

C10A LIPID MODIFYING AGENTS, PLAIN

C10A A HMG CoA reductase inhibitors

C10A B Fibrates

C10A C Bile acid sequestrants

❖ PCSK9 inhibitors is classified in C10AX

C10A D

+ Nicotinic acid and derivatives

C10A X Other lipid modifying agents

➤ Colestilan is classified in V03A.

➤ PCSK9 inhibitors are classified here.

❖

C10B LIPID MODIFYING AGENTS, COMBINATIONS

➤ Lipid-regulating cardiovascular multitherapy combination products are classified here.

❖

EphMRA (Product Based)

C9X OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

C10 LIPID-REGULATING/ANTI-ATHEROMA PREPARATIONS

C10A CHOLESTEROL AND TRIGLYCERIDE REGULATING PREPARATIONS

C10A 1 Statins (HMG-CoA reductase inhibitors)

C10A 2 Fibrates

C10A 3 Ion-exchange resins

➤ Colestilan is also classified in V3G.

C10A4 PCSK9 inhibitors

C10A 9 All other cholesterol/triglyceride regulators

C10 B ANTI-ATHEROMA PREPARATIONS OF NATURAL ORIGIN

C10C LIPID REGULATORS IN COMBINATION WITH OTHER LIPID REGULATORS

➤ Lipid-regulating cardiovascular multitherapy combination products are classified in C11A.

C11 CARDIOVASCULAR MULTI-THERAPY COMBINATION PRODUCTS

WHO (Substance Based)

- ❖ ➤ Lipid-regulating cardiovascular multitherapy combination products are classified in C10B

D DERMATOLOGICALS

D01 ANTIFUNGALS FOR DERMATOLOGICAL USE

D01A ANTIFUNGALS FOR TOPICAL USE

- Topical metronidazole is mainly used for rosacea and is classified in D06B X.
- Combinations with corticosteroids are classified here.

D01B ANTIFUNGALS FOR SYSTEMIC USE

- Terbinafine is classified here.

D02 EMOLLIENTS AND PROTECTIVES

D02A EMOLLIENTS AND PROTECTIVES

- + ➤ Aminobenzoic acid is classified in D02B.

D02B PROTECTIVES AGAINST UV-RADIATION

- Betacarotene is classified here.
- Aminobenzoic acid is classified here.

D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS

- Local haemostatics are classified in B02B.
- Bromelains is classified in B06A A.

EphMRA (Product Based)

- C11A LIPID-REGULATING CARDIOVASCULAR MULTI-THERAPY COMBINATION PRODUCTS

D DERMATOLOGICALS

D1 ANTIFUNGALS, DERMATOLOGICAL

D1A1 Topical dermatological antifungals

- Products indicated for the treatment of rosacea are classified in D10A.
- Combinations with corticosteroids are in D7B2.

D1A2 Systemic dermatological Antifungals

- Terbinafine is classified in J2A.

D2 EMOLLIENTS, PROTECTIVES

D2A EMOLLIENTS, PROTECTIVES

- Aminobenzoic acid is classified here.
- Betacarotene is classified in D11A.

D3 WOUND HEALING AGENTS

- Local haemostatics are classified here.
- Bromelains is classified here or in A9A and V3H depending on indications.

WHO (Substance Based)

- Chymotrypsin is classified in B06A A when used as haematological enzymes.

D03A CICATRIZANTS



D03B ENZYMES

D03B A ➤ Bromelains is classified here.



- Bromelains is classified in A9A, D3A or V3H depending on indication

D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.

D4

ANTIPRURITICS, INCL. TOPICAL ANTIHISTAMINES, ANAESTHETICS, ETC.

D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC

- Nalfurafine is classified in V03A.

D4A

ANTIPRURITICS, INCL. ANTIHISTAMINES, ANAESTHETICS, ETC.

- Nalfurafine is classified here.

D05 ANTIPSORIATICS

- Methoxsalen is classified in D05A or D05B, depending on formulation.

D5

NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS

Methoxsalen when indicated for cancer therapy is classified in L1X8.

D05A ANTIPSORIATICS FOR TOPICAL USE

D05B ANTIPSORIATICS FOR SYSTEMIC USE

- Alefacept, ixekizumab, secukinumab, risankizumab, ustekinumab, and apremilast are classified in L04A.

D5A

TOPICAL ANTIPSORIASIS PRODUCTS

D5B

SYSTEMIC ANTIPSORIASIS PRODUCTS

- Alefacept, ixekizumab, secukinumab, risankizumab, and ustekinumab when indicated for psoriasis are classified here.

WHO (Substance Based)

- Methotrexate is classified in L01B and L04A.
- Tildrakizumab is classified in L04A.

EphMRA (Product Based)

- Apremilast when indicated for only psoriatic skin conditions is classified here. When indicated for other conditions it is classified in L4X.
- Ixekizumab, ustekinumab and secukinumab when indicated for psoriasis and also for other conditions is classified in L4C.
- Methotrexate is classified in D5B, M1C and L1B.
- Tildrakizumab is classified here.



- Topical tacrolimus is classified in D11A.
- Alitretinoin is classified in D11A.
- Dupilumab is classified in D11A

D5X

OTHER NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS

- Topical tacrolimus is classified here.
- Alitretinoin is classified in here when indicated for the treatment of eczema, and in L1X1 when indicated to treat cutaneous lesions in Kaposi's sarcoma.
- Products containing ingenol mebutate or diclofenac gel that are indicated for actinic keratosis are classified here
- Dupilumab is classified here when indicated for the treatment of atopic dermatitis, and in L4C when also indicated for asthma.

D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE

- Metronidazole for the treatment of rosacea is classified here.
- Dressings with anti-infectives are classified in D09A A.

D06A ANTIBIOTICS FOR TOPICAL USE

- Ozenoxacin is classified here.

D6 TOPICAL ANTIBACTERIALS AND ANTIVIRALS

- Metronidazole for treatment of rosacea is classified in D10A.
- Dressings with anti-infectives are classified here.

D6A TOPICAL ANTIBACTERIALS

- Ozenoxacin for treatment of acne is classified in D10A

WHO (Substance Based)

D06B CHEMOTHERAPEUTICS FOR TOPICAL USE
(- D6B B)

D06B B Antivirals

D6C ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS

D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS

D07A CORTICOSTEROIDS, PLAIN

D07B CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS

+

D07C CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS

+

D07X CORTICOSTEROIDS, OTHER COMBINATIONS

D08 ANTISEPTICS AND DISINFECTANTS

D08A ANTISEPTICS AND DISINFECTANTS

EphMRA (Product Based)

D6A TOPICAL ANTIBACTERIALS

D6D TOPICAL ANTIVIRALS INFECTION PRODUCTS

❖ Included in D6A

D7 TOPICAL CORTICOSTEROIDS

D7A PLAIN TOPICAL CORTICOSTEROIDS

D7B TOPICAL CORTICOSTEROID COMBINATIONS

❖

❖

D8 ANTISEPTICS AND DISINFECTANTS

D8A ANTISEPTICS AND DISINFECTANTS

WHO (Substance Based)

D09 MEDICATED DRESSINGS



D09A MEDICATED DRESSINGS

This group comprises medicated dressings, ointment dressings etc. Liquid wound protectives are classified in D02A D – Liquid plasters. Local hemostatics, eg. Gauze, tampons etc. are classified in B02B C – Local hemostatics.

D09A A Ointment dressings with antiinfectives

D09A B Zinc bandages

D09A X Soft paraffin dressings

EphMRA (Product Based)



THE PRODUCTS OF THIS CLASS HAVE BEEN ALLOCATED TO THE DIFFERENT GROUPS

Inc in D6A TOPICAL ANTIBIOTICS AND/OR SULPHONAMIDES

Inc in D5A TOPICAL ANTIPSORIASIS AND SIMILAR PRODUCTS

Inc in D2A EMOLLIENTS, PROTECTIVES

D10 ANTI-ACNE PREPARATIONS

D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE

- Metronidazole for the treatment of rosacea is classified in D06B.
- Brimonidine is classified in D11A and in S1E for ocular indications.
- Nadifloxacin is classified here.
- Non-ophthalmic sulfacetamide is classified here.
- Ozenoxacin is classified in D06A.

D10 ANTI-ACNE PREPARATIONS

D10A TOPICAL ANTI-ACNE PREPARATIONS

- Metronidazole for the treatment of rosacea is classified here.
- Brimonidine is classified here and in S1E for ocular indications.
- Nadifloxacin is classified here and in D6A when indicated for skin bacteriosis.
- Non-ophthalmic sulfacetamide is classified here and in D6A when indicated for skin bacteriosis.
- Ozenoxacin when used to treat acne is classified here; otherwise it is classified in D6A.

WHO (Substance Based)

- D10B ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE
- Antibiotics, such as tetracyclines and erythromycin, which are also used for the treatment of acne are classified in group J.
 - Combinations of estrogen and antiandrogen, used for the treatment of acne, are classified in group G03H.

-
- D11 OTHER DERMATOLOGICAL PREPARATIONS
- D11A OTHER DERMATOLOGICAL PREPARATIONS
- Androgens for topical use are classified here.
 - Tacrolimus and pimecrolimus are classified here.
 - Alitretinoin is classified here.
 - Brimonidine is classified here and in S1E for ocular indications.
 - Ivermectin is classified here and in P02C.
 - Dupilumab is classified here.

-
- G GENITO URINARY SYSTEM AND SEX HORMONES
- G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS

EphMRA (Product Based)

- D10B ORAL ANTI-ACNE PREPARATIONS
- Antibiotic products, specifically indicated for the treatment of acne are classified here.
 - Combinations of estrogen and cyproterone, specifically indicated for the treatment of acne, are classified here.
 - Products indicated for both oral contraception and acne are classified in G3A

-
- D11 OTHER DERMATOLOGICAL PREPARATIONS
- D11A OTHER DERMATOLOGICAL PREPARATIONS
- Androgens for topical use are in D3A.
 - Tacrolimus is classified in D5X and L4A; pimecrolimus in D5X.
 - Alitretinoin is classified in D5X when indicated for the treatment of eczema, and in L1X1 when indicated to treat cutaneous lesions in Kaposi's sarcoma.
 - Brimonidine is classified in D10A and in S1E for ocular indications.
 - Ivermectin is classified in P1B and in P3A, depending on indication.
 - Dupilumab is classified in D5X, when indicated only for atopic dermatitis and in L4C when also indicated for asthma.

-
- G GENITO-URINARY SYSTEM AND SEX HORMONES
- G1 GYNAECOLOGICAL ANTI-INFECTIVES

WHO (Substance Based)

G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS

+ ➤ All oral and rectal dosage forms of imidazole derivatives are classified in P01A.

G01B ANTIINFECTIVES AND ANTISEPTICS, IN COMBINATION WITH CORTICOSTEROIDS

G02 OTHER GYNAECOLOGICALS

➤ Analgesics used in dysmenorrhea are classified in N02B.

G02A UTEROTONICS

➤ Oxytocin and demoxytocin are classified in H01B.

G02B CONTRACEPTIVES FOR TOPICAL USE

➤ IUDs containing progestogens are classified here.

G02C OTHER GYNECOLOGICALS

➤ Vaginal forms of estrogens are classified in G03C.

G02C A Sympathomimetics, labor repressants

EphMRA (Product Based)

G1A TRICHOMONACIDES

+ ➤ Dosage forms used for treatment of gynaecological infections are classified here.
➤ Rectal suppositories for topical trichomonoacides are classified in J8B.

G1B GYNAECOLOGICAL ANTIFUNGALS

+

G1C GYNAECOLOGICAL ANTIBACTERIALS

+

G1D GYNAECOLOGICAL ANTISEPTICS

G2 OTHER GYNAECOLOGICALS

➤ Analgesics indicated exclusively for dysmenorrhea are classified in G2X1.

G2A UTEROTONIC PRODUCTS

➤ Oxytocin and demoxytocin are classified here.

G2B TOPICAL CONTRACEPTIVES

➤ IUDs with progestogens are classified in G3A.

❖

➤ Vaginal forms of estrogens are classified in G2F.

G2E LABOUR INHIBITORS

WHO (Substance Based)

EphMRA (Product Based)



➤ Vaginal forms of estrogens are classified in G03C.

G2F

TOPICAL SEX HORMONES

➤ Vaginal forms of estrogens are classified here.

G02C B Prolactin inhibitors

- Lisuride tablets in high strength (0.2mg) are classified in this group, while low dose tablets (25 mcg) are classified in N02C.
- Bromocriptine low dose is classified here; high strength tablets are classified in N04B.
- Cabergoline low dose is classified here, high strength tablets are classified in N04B.

G2D

PROLACTIN INHIBITORS

- Lisuride is classified in N4A.
- Bromocriptine is classified here and N4A.
- Cabergoline is classified here and N4A.

G02C C Antiinflammatory products for vaginal administration

G2X

OTHER GYNAECOLOGICAL PRODUCTS



G02C X Other gynaecologicals

G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

G3

SEX HORMONES AND PRODUCTS WITH SIMILAR DESIRED EFFECTS, SYSTEMIC ACTION ONLY

G03A HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE

- IUDs with progestogens are classified in G02B.
- Ulipristal when indicated for emergency contraception is classified here. It is also classified in G03X.
- Mifepristone is classified in G03XB.

G3A

HORMONAL CONTRACEPTIVES, SYSTEMIC

- IUDs with progestogens are classified here.
- Ulipristal when indicated for emergency contraception is classified here. It is also classified in G3X.
- Mifepristone (10-25 mg) when indicated for emergency contraception is classified here. It is also classified in G3X.
- Products indicated for both oral contraception and acne are classified here.

WHO (Substance Based)

EphMRA (Product Based)

G03B	ANDROGENS	G3B	ANDROGENS, EXCLUDING G3E, G3F
G03C	ESTROGENS <ul style="list-style-type: none"> ➤ Tibolone is classified here. ➤ Vaginal forms are classified here. 	G3C	OESTROGENS, EXCLUDING G3A, G3E, G3F <ul style="list-style-type: none"> ➤ Tibolone is classified G3X. ➤ Parenteral conjugated oestrogens for uterine bleeding are classified in B2G. <p>Vaginal forms and transdermal patches for local effect are classified in G2F.</p>
G03D	PROGESTOGENS <ul style="list-style-type: none"> ➤ Flumedroxone is classified in N02C. 	G3D	PROGESTOGENS, EXCLUDING G3A, G3F <ul style="list-style-type: none"> ➤ Flumedroxone is classified here.
G03E	ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION	G3E	ANDROGEN WITH FEMALE HORMONE COMBINATIONS
G03F	PROGESTOGENS AND ESTROGENS IN COMBINATION <ul style="list-style-type: none"> ➤ Estradiol and cyproterone in combination is classified in G03H B. 	G3F	OESTROGEN WITH PROGESTOGEN COMBINATIONS, EXCLUDING G3A <ul style="list-style-type: none"> ➤ Estradiol and cyproterone in combination is classified here.
G03G	GONADOTROPHINS AND OTHER OVULATION STIMULANTS	G3G	GONADOTROPHINS, INCL. OTHER OVULATION STIMULANTS
G03H	ANTIANDROGENS <ul style="list-style-type: none"> ➤ All plain cyproterone preparations (and combinations of cyproterone and estrogen) regardless of indication are classified here. 	❖	<ul style="list-style-type: none"> ➤ Plain cyproterone preparations are classified in G3X and L2B depending on indication.

WHO (Substance Based)



- Bazedoxifene, lasofoxifene, ospemifene and raloxifene are classified in G03X.

G03X

OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

- Tibolone is classified in G03D C.
- Bazedoxifene, lasofoxifen, raloxifene, and ospemifene are classified here.
- All plain cyproterone preparations (and combinations of cyproterone and estrogen) regardless of indication are classified in G03H.
- Ulipristal for emergency contraception is classified in G03A D.
- Mifepristone is classified here.
- Vaginal forms of prasterone are classified here.

G04

UROLOGICALS



- Urinary quinolones are in J01M.
- Other urinary antibacterials are in J01X.
- Plazomicin is classified in J01G.

EphMRA (Product Based)

G3J

SERMS (SELECTIVE OESTROGEN RECEPTOR MODULATORS)

- Bazedoxifene, lasofoxifene, ospemifene and raloxifene are classified here.

G3X

OTHER SEX HORMONES AND SIMILAR PRODUCTS

- Tibolone is classified here
- Products containing cyproterone are classified according to indication.
- Combinations of estrogen and cyproterone are classified in D10B (DIANE 35) and G3F (CLIMEN).
- Bazedoxifene, lasofoxifen, raloxifene, and ospemifene are classified in G3J.
- Plain cyproterone preparations are classified here and in L2B depending on indication.
- Ulipristal is also classified in G3A6 when indicated for emergency contraception.
- Mifepristone is also classified in G3A6 when indicated for emergency contraception.
- Vaginal forms of prasterone are classified in G2F.

G4

UROLOGICALS

G4A

URINARY ANTI-INFECTIVES AND ANTISEPTICS

- Urinary quinolones are here in G4A2.
- Other antiseptics and anti-bacterials are here in G4A9.
- Plazomicin is here in G4A1.

WHO (Substance Based)

- G04B UROLOGICALS
- Drugs used in erectile dysfunction are here in G04B E.
 - Urinary antispasmodics are here in G04B D.

- G04C DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
- Indoramin is classified in C02CA.
 - Drugs for benign prostatic hypertrophy plus a PDE5 inhibitor are classified here.



- Phentolamine used as an antidote is in V03A. It is only in G04B for erectile dysfunction when in combinations.
- PDE5 inhibitors are classified in G04BE.
- Drugs for benign prostatic hypertrophy plus a PDE5 inhibitor are classified in G04C A.



- Other urologicals are in G04B.

EphMRA (Product Based)



- Other urologicals are in G4X with exceptions below.
- Erectile dysfunction products are in G4E.
- Urinary incontinence products are in G4D.

G4C BPH (BENIGN PROSTATIC HYPERTROPHY) PRODUCTS

- Indoramin when indicated for BPH or hypertension is classified in C2A2.
- Indoramin when indicated for migraine is classified in N2C9.

G4D

URINARY INCONTINENCE PRODUCTS

G4E

ERECTILE DYSFUNCTION PRODUCTS

- Phentolamine for erectile dysfunction is here. It is in V3X when used as an antidote.
- PDE5 inhibitors when indicated only for PAH are classified in C6B2.

G4X

ALL OTHER UROLOGICAL PRODUCTS

WHO (Substance Based)

H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

The classification of these hormonal products is based according to the origin of the hormones and not according to their indication.

H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES



H01A ANTERIOR PITUITARY LOBE HORMONES and ANALOGUES

H01A A ACTH

H01A B Thyrotropin

H01A C Somatotropin and somatotropin agonists



H01A X Other anterior pituitary lobe hormones and analogues

➤ Pegvisomant is classified here.

H01B POSTERIOR PITUITARY LOBE HORMONES

H01B A Vasopressin and analogues

➤ Terlipressin is classified here.

H01B B Oxytocin and analogues

H01C HYPOTHALAMIC HORMONES

EphMRA (Product Based)

H SYSTEMIC HORMONAL PREPARATIONS (EXCL. SEX HORMONES)

H1 PITUITARY AND HYPOTHALAMIC HORMONES

H1A ACTH

Inc in H3A THYROID PREPARATIONS

H4C GROWTH HORMONES



➤ Pegvisomant is classified in H1C2.



H4D ANTIDIURETIC HORMONES

➤ Terlipressin is classified in B2G.

G2A LABOUR INDUCERS

H1C HYPOTHALAMIC HORMONES

WHO (Substance Based)

- H01C A Gonadotrophin-releasing hormones
- Gonadorelin and nafarelin are classified here.
 - Buserelin, goserelin, histrelin, leuprorelin, and triptorelin are classified in L02A E.
- H01C B Somatostatin and analogues
- H01C C ANTI-GONADOTROPHIN-RELEASING HORMONES

H02 CORTICOSTEROIDS FOR SYSTEMIC USE

H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN

H02B CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS

H02C ANTIADRENAL PREPARATIONS

- Trilostane is classified here.

H03 THYROID THERAPY

H03A THYROID PREPARATIONS

- Thyrotrophin is classified in H01A.

H03B ANTITHYROID PREPARATIONS

H03C IODINE THERAPY

EphMRA (Product Based)

- H1C1 GONADOTROPHIN RELEASING HORMONES
- Gonadotrophin-releasing hormone analogues buserelin, goserelin, nafarelin, leuprorelin, and triptorelin when used for cancer are classified in L2A3.
- H1C2 ANTIGROWTH HORMONES
- Pegvisomant is classified here.
- H1C3 ANTIGONADOTROPHIN-RELEASING HORMONES

H2 SYSTEMIC CORTICOSTEROIDS

H2A SYSTEMIC CORTICOSTEROIDS, PLAIN

H2B SYSTEMIC CORTICOSTEROID COMBINATIONS



- Trilostane is classified in H4X.

H3 THYROID THERAPY

H3A THYROID PREPARATIONS

- Thyrotrophin is classified here.

H3B ANTI-THYROID PREPARATIONS

H3C IODINE THERAPY

WHO (Substance Based)

H04 PANCREATIC HORMONES



H04A GLYCOGENOLYTIC HORMONES



EphMRA (Product Based)

H4B GLUCAGON

H05 CALCIUM HOMEOSTASIS



H05A PARATHYROID HORMONES AND ANALOGUES

H4E PARATHYROID HORMONES AND ANALOGUES

H05B ANTI-PARATHYROID HORMONES



H05B A Calcitonin preparations

H4A CALCITONINS

H05B X Other anti-parathyroid agents

H4F ANTIPARATHYROID PRODUCTS

J ANTIINFECTIVES FOR SYSTEMIC USE

J GENERAL ANTI-INFECTIVES SYSTEMIC

J01 ANTIBACTERIALS FOR SYSTEMIC USE

J1 SYSTEMIC ANTIBACTERIALS

J01A TETRACYCLINES

J1A TETRACYCLINES AND COMBINATIONS

➤ Tigecycline is classified here.

➤ Tigecycline is classified in J1X.

J01B AMPHENICOLS

J1B CHLORAMPHENICOL AND COMBINATIONS

J01C BETA-LACTAM ANTIBACTERIALS, PENICILLINS

J1C BROAD SPECTRUM PENICILLINS



J1H MEDIUM AND NARROW SPECTRUM PENICILLINS

WHO (Substance Based)

EphMRA (Product Based)

		+	
		J1L	CARBENICILLIN AND SIMILAR TYPES
J01D	OTHER BETA LACTAM ANTIBACTERIALS	❖	
J01D B-E	<ul style="list-style-type: none"> ➤ First-fourth generation cephalosporins. ➤ Loracarbef is classified here in J01D C. ➤ Other cephalosporins (including ceftobiprole medocaril and ceftaroline fosamil) are classified in J01D I. 	J1D	CEPHALOSPORINS
J01D F	Monobactams	J1D1-2	<ul style="list-style-type: none"> ➤ Oral – injectable cephalosporins. ➤ Loracarbef is classified in J1P3. ➤ Other cephalosporins (including ceftobiprole medocaril and ceftaroline fosamil) are classified here.
J01D H	Carbapenems	J1P1	Monobactams
+		J1P2	Penems and carbapenems
J01D I	Other cephalosporins and penems		<ul style="list-style-type: none"> ➤ Other cephalosporins (including ceftobiprole medocaril and ceftaroline fosamil) are classified in J1D.
J01E	SULFONAMIDES AND TRIMETHOPRIM	J1E	TRIMETHOPRIM AND SIMILAR FORMULATIONS
		+	
		J3A	SYSTEMIC SULFONAMIDES
J01F	MACROLIDES, LINCOSAMIDES and STREPTOGRAMINS	J1F	MACROLIDES AND SIMILAR TYPES
	<ul style="list-style-type: none"> ➤ Pristinamycin is classified here. 		<ul style="list-style-type: none"> ➤ Pristinamycin is classified in J1X.
J01G	AMINOGLYCOSIDE ANTIBACTERIALS	J1K	AMINOGLYCOSIDES
	<ul style="list-style-type: none"> ➤ Plain streptomycin is classified here. 		<ul style="list-style-type: none"> ➤ Streptomycin is classified in J1X.

WHO (Substance Based)

➤ Plazomicin is classified here.

J01M QUINOLONE ANTIBACTERIALS

J01R COMBINATIONS OF ANTIBACTERIALS

Sulfonamides, combinations with other antibacterials (excl. trimethoprim) are classified here.

➤ Monobactams, carbapenems, carbacephem are classified in J01D.

J01X OTHER ANTIBACTERIALS

➤ Pristinamycin is classified J01F; Tigecyclin is in J01A.

➤ Parenteral imidazole formulations are classified here in J01X D.

J02 ANTIMYCOTICS FOR SYSTEMIC USE

J02A ANTIMYCOTICS FOR SYSTEMIC USE

➤ Terbinafine and griseofulvin are classified in D01B.

EphMRA (Product Based)

➤ Plazomicin is classified in G4A1

J1G FLUOROQUINOLONES

➤ Non-halogenated quinolones are in G4A2.

❖

Combinations of antibacterials are classified based on classification hierarchy. See guidelines for details.

Sulfonamides in combinations with other antibacterials (excl. trimethoprim) are classified in J3A.

J1P OTHER BETA-LACTAM ANTIBACTERIALS, EXCLUDING PENICILLINS, CEPHALOSPORINS

➤ Monobactams, carbapenems, carbcephems are classified here.

J1X OTHER ANTIBACTERIALS

➤ Pristinamycin and tigecyclin are classified here.

➤ Parenteral imidazole formulations are classified in J8B.

J2 SYSTEMIC AGENTS FOR FUNGAL INFECTIONS

J2A SYSTEMIC AGENTS FOR FUNGAL INFECTIONS

➤ Terbinafine for systemic use is classified here.

➤ Griseofulvin is classified in D1A2.

WHO (Substance Based)



- All plain sulphonamides are classified in J01E. Sulfonamides, combinations with other antibacterials (excl. trimethoprim) are classified in J01R.



- J04 ANTIMYCOBACTERIALS**
J04A DRUGS FOR TREATMENT OF TUBERCULOSIS
- Rifampicin and rifamycin are classified here.
 - Plain streptomycin is classified in J01G A.

J04B DRUGS FOR TREATMENT OF LEPRA

- J05 ANTIVIRALS FOR SYSTEMIC USE**
J05A DIRECT ACTING ANTIVIRALS

- Antivirals acting against HIV are classified here in J05A E–J05A G, and J05A X depending on inhibition mechanism. HIV combination products are classified in J05AR.
- Cobicistat is classified in V03AX.

EphMRA (Product Based)

J3

SYSTEMIC SULPHONAMIDES

- This group includes plain sulphonamides and sulphonamide/ antibiotic combinations, excluding trimethoprim/ sulphonamides which are classified J1E.

J3

SYSTEMIC SULPHONAMIDES

J4

ANTIMYCOBACTERIALS

J4A

ANTITUBERCULAR PRODUCTS

- Rifampicin and rifamycin are classified here and in J1M.
- Streptomycin is classified here.

J4B

DRUGS FOR THE TREATMENT OF LEPRA

J5

ANTIVIRALS FOR SYSTEMIC USE

J5B

ANTIVIRALS, OTHER

- The combination of ribavirin and peginterferon is classified in J5D1.

+

J5C

HIV ANTIVIRALS

- HIV antivirals are classified here in J5C1 – J5C5 depending on inhibition mechanism. Combinations of different classes of HIV antivirals are classified in J5C9.

+

- Cobicistat is classified here in J5C9.

WHO (Substance Based)



- Antivirals against HCV are classified here in J05AP
- Antivirals against HBV are mainly classified in J05AF. No separate group for HBV agents,
- The combination of ribavirin and peginterferon is classified in L03A

EphMRA (Product Based)

- J5D HEPATITIS ANTIVIRALS
- The combination of ribavirin and peginterferon is classified in J5D1

J06 IMMUNE SERA AND IMMUNOGLOBULINS

J06A IMMUNE SERA

J06B IMMUNOGLOBULINS

J6 SERA AND GAMMA-GLOBULIN

J6A ANTITOXIC SERA

J6C POLYVALENT IMMUNO-GLOBULINS - INTRAVENOUS

+

J6D HOMOLOGOUS IMMUNOLOGICALLY ACTIVE GLOBULINS - INTRAVENOUS

+

J6E POLYVALENT IMMUNO-GLOBULINS - INTRAMUSCULAR

+

J6F POLYVALENT IMMUNO-GLOBULINS – COMBINATION MODULATION - MAINLY INTRAMUSCULAR

+

J6G SPECIFIC IMMUNOGLOBULINS - ANTIBACTERIAL

WHO (Substance Based)

EphMRA (Product Based)

		+	
		J6H	SPECIFIC IMMUNOGLOBULINS - ANTIVIRAL
		+	
		J6J	OTHER SPECIFIC IMMUNOGLOBULINS
J07	VACCINES	J7	VACCINES
J07A	BACTERIAL VACCINES	J7D	BACTERIAL VACCINES
	<ul style="list-style-type: none"> ➤ Also includes combinations of bacterial vaccines. ➤ BCG vaccine is classified in L03A X. 		<ul style="list-style-type: none"> ➤ Includes vaccines against one bacterial group. All combinations acting against more than one group of virus or bacteria are classified in J7B. ➤ BCG vaccine as a tuberculosis vaccine is classified here. BCG vaccine for cancer is classified in L1X9 and for general immunostimulation in L3A9.
J07B	VIRAL VACCINES	J7E	VIRAL VACCINES
	<ul style="list-style-type: none"> ➤ Also includes combinations of viral vaccines. 		<ul style="list-style-type: none"> ➤ Includes vaccines against one viral group. All combinations acting against more than one group of virus or bacteria are classified in J7B.
❖		J7F	PROTOZOAL VACCINES
			<ul style="list-style-type: none"> ➤ Includes vaccines against one protozoal group. Vaccines against a combination of organisms are classified in J7B.
J07C	BACTERIAL AND VIRAL VACCINES, COMBINED	J7B	COMBINATIONS OF VACCINES
	<ul style="list-style-type: none"> ➤ Bacterial vaccines combinations and viral vaccines combination are classified J07A and J07B respectively. 		<ul style="list-style-type: none"> ➤ All combinations of bacterial, viral, and protozoal vaccines are classified here.

WHO (Substance Based)

J07X OTHER VACCINES



➤ Parenteral imidazole formulations are classified in J01X D.

L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

L01 ANTINEOPLASTIC AGENTS

L01A ALKYLATING AGENTS

➤ Altretamine is classified in L01X.

L01B ANTIMETABOLITES

➤ Methotrexate is classified in L01B and L04A.

➤ Cladribine when indicated for multiple sclerosis is classified in L04A.

L01C PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS

➤ Irinotecan, topotecan, and belotecan are classified in L01X X.

➤ Products for cancer containing omacetaxine mepisuccinate are classified in L01X X.

L01D CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES

EphMRA (Product Based)

J7X ALL OTHER VACCINE –LIKE PRODUCTS

J8 OTHER ANTI-INFECTIVES

➤ Parenteral imidazole formulations are classified here in J8B.

L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

L1 CYTOSTATICS

L1A ALKYLATING AGENTS

➤ Altretamine is classified here.

L1B ANTIMETABOLITES

➤ Methotrexate is classified in D5B, M1C and L01B.

➤ Cladribine when indicated for multiple sclerosis is classified in N7A.

L1C PLANT-BASED ANTINEOPLASTICS

➤ Irinotecan, topotecan, and belotecan are classified here.

➤ Products for cancer containing omacetaxine mepisuccinate are classified here.

L1D ANTINEOPLASTIC ANTIBIOTICS

WHO (Substance Based)

- L01X OTHER ANTINEOPLASTIC AGENTS
- Altretamine is classified here.
 - Alitretinoin is classified in D11A.
 - Irinotecan, topotecan, and belotecan are classified here in L01X X.
 - Ibritumomab tiuxetan, tositumomab and iodine (131I) tositumomab are classified in V10X.

L01X A Platinum compounds

L01X B Methylhydrazines

L01X C Monoclonal Antibodies

- Alemtuzumab is classified in L04A A.

L01X D Sensitizers used in photodynamic/radiation therapy

- Methoxsalen is classified in D05A or D05B depending on formulation.

L01X E Protein kinase inhibitors

- Ruxolitinib is classified here.
- Alpelisib is classified in L01X X

❖ Proteasome inhibitors are classified in L01X X

EphMRA (Product Based)

- L1X ALL OTHER ANTINEOPLASTICS
- Altretamine is classified in L1A.
 - Irinotecan, topotecan, and belotecan are classified in L1C.
 - Ibritumomab tiuxetan, tositumomab and iodine (131I) tositumomab are classified here.

L1F PLATINUM ANTINEOPLASTICS

L1X9 All other antineoplastics

L1G MONOCLONAL ANTIBODY ANTINEOPLASTICS

- Alemtuzumab when indicated for multiple sclerosis is classified in N7A.

L1X8 Photosensitisers for cancer therapy

- Methoxsalen when used for cancer therapy is classified here; otherwise it is classified in D5A or D5B, depending on formulation.

L1H PROTEIN KINASE INHIBITOR ANTINEOPLASTICS

- Ribociclib + letrozole is classified here.
- Ruxolitinib is classified here.
- Alpelisib is classified here.

L1J PROTEASOME INHIBITOR ANTINEOPLASTICS

WHO (Substance Based)

- L01X X Other antineoplastic agents
- Sipuleucel-T is classified in L03X A.
 - Aflibercept for metastatic colorectal cancer is classified here and for macular degeneration is classified in S01L.
 - Products for cancer containing omacetaxine mepisuccinate are classified here.
 - Proteasome inhibitors are classified here.
 - Lenalidomide, pomalidomide, and thalidomide are classified in L04A
 - Tasonermin is classified in L03A X.
 - BCG vaccine is classified in L03A X.
 - Alpelisib is classified here.
 - Miltefosine is classified in P01C.

EphMRA (Product Based)

- L1X1 Alternative preparations for cancer therapy
- +
- Alitretinoin is classified here when indicated to treat cutaneous lesions in Kaposi's sarcoma and in D5X when indicated for the treatment of eczema.
- L1X2 Lidomide antineoplastics
- +
- L1X3 HDAC inhibitor antineoplastics
- +
- L1X9
- All other antineoplastics
- Sipuleucel-T is classified here.
 - Aflibercept is classified here and in S1P.
 - Products for cancer containing omacetaxine mepisuccinate are classified in L1C.
 - Tasonermin is classified here.
 - Alpelisib is classified in L1H.
 - BCG vaccine for cancer is classified here. BCG vaccine for general immunostimulation is classified in L3A9. BCG vaccine for tuberculosis vaccination is classified in J7D6.
 - Miltefosine for oncology indications is classified here. When indicated for treatment of leishmaniasis and free-living amoeba it is classified in P1G.

WHO (Substance Based)

L02 ENDOCRINE THERAPY

L02A HORMONES AND RELATED AGENTS

L02A A Estrogens

L02A B Progestogens

L02A E Gonadotrophin releasing hormone analogues

➤ Buserelin, goserelin, histrelin, leuprorelin, and triptorelin are classified here.

➤ Gonadorelin and nafarelin are classified in H01C A.

L02A X Other Hormones

L02B HORMONE ANTAGONISTS AND RELATED AGENTS

L02B A Anti-estrogens

➤ Fulvestrant is classified here.

L02B B Anti-androgens

➤ All plain cyproterone preparations (and combinations of cyproterone and estrogen) regardless of indication are classified here.

➤ Abiraterone is classified in L02B X.

L02B G Aromatase inhibitors

L02B X Other hormone antagonists and related agents

➤ Abiraterone is classified here.

➤ Fulvestrant is classified in L02B A.

EphMRA (Product Based)

L2 CYTOSTATIC HORMONE THERAPY

L2A CYTOSTATIC HORMONES

L2A1 Cytostatic oestrogens

L2A2 Cytostatic progestogens

L2A3 Cytostatic gonadotrophin releasing hormone analogues

➤ Gonadotrophin-releasing hormone analogues buserelin, goserelin, leuprorelin, and triptorelin are classified here and in H1C1.

L2A9 Other cytostatic hormones

L2B CYTOSTATIC HORMONE ANTAGONISTS

L2B1 Cytostatic anti-estrogens

➤ Fulvestrant is classified in L2B9.

L2B2 Cytostatic anti-androgens

➤ Plain cyproterone preparations are classified here and in G3X depending on indication.

➤ Abiraterone is classified here.

L2B3 Cytostatic aromatase inhibitors

➤ Ribociclib + letrozole is classified in L1H5

L2B9 Other cytostatic hormone antagonists

➤ Abiraterone is classified in L2B2.

➤ Fulvestrant is classified here.

WHO (Substance Based)

L03 IMMUNOSTIMULANTS

L03A IMMUNOSTIMULANTS

➤ Levamisole is classified in P02C E.

L03A A Colony stimulating factors

L03A C + Interleukins +

L03A X Other cytokines and immunomodulators

➤ Sipuleucel-T is classified here.

➤ Tasonermin is classified here.

➤ BCG vaccine is classified here.

L03A B INTERFERONS

L04 IMMUNOSUPPRESSANTS

L04A IMMUNOSUPPRESSANTS

L04A A Selective immunosuppressants

➤ Alefacept is classified here.

➤ Abatacept, alemtuzumab, tocilizumab are classified here.

EphMRA (Product Based)

L3 IMMUNOMODULATING AGENTS

L3A IMMUNOSTIMULATING AGENTS, EXCL. INTERFERONS

➤ Levamisole, when indicated as immunostimulant, is classified here

L3A1 COLONY STIMULATING FACTORS

L3A9 All other immunostimulating agents excluding interferons

➤ Sipuleucel-T is classified in L1X9.

➤ Tasonermin is classified in L1X9.

➤ BCG vaccine for general immunostimulation is classified here. BCG vaccine for tuberculosis vaccination is classified in J7D6. BCG vaccine for cancer is classified in L1X9.

L3B INTERFERONS

➤ Interferons indicated for viral hepatitis only are classified in J5D

➤ Interferons indicated for multiple sclerosis only are classified in N7A.

L4 IMMUNOSUPPRESSIVE AGENTS

+

❖

➤ Alefacept is classified in D5B.

Inc in L4X ➤ Abatacept and tocilizumab are classified in M1C.

➤ Alemtuzumab is classified in L1G and N7A.

WHO (Substance Based)

- Vedolizumab is classified here.
 - Fingolimod and siponimod are classified here.
 - Baricitinib is classified here.
 - Natalizumab and ocrelizumab are classified here.
 - Apremilast is classified here.
 - Cladribine when indicated for multiple sclerosis is classified here. When indicated for cancer it is classified in L01B.
 - Tofacitinib and leflunomide are classified here.
 - Upadacitinib is classified here.
- L04A B TNF- α inhibitors
- L04A C Interleukin inhibitors
- Anakinra, sarilumab, ixekizumab, secukinumab, risankizumab, ustekinumab, and daclizumab are classified here.
 - Dupilumab is classified in D11A.
 - Tildrakizumab is classified here.

EphMRA (Product Based)

- Vedolizumab is classified in A7E.
 - Fingolimod and siponimod when indicated for multiple sclerosis only are classified in N7A.
 - Baricitinib is classified in M1C.
 - Natalizumab and ocrelizumab are classified in N7A.
 - Apremilast when indicated for psoriatic skin conditions only is classified in D5B. When indicated for other conditions it is classified in L4X.
 - Cladribine when indicated for multiple sclerosis is classified in N7A. When indicated for cancer it is classified in L1B.
 - Tofacitinib and leflunomide when indicated for rheumatoid arthritis only are classified in M1C.
 - Upadacitinib is classified in M1C.
- L4B ANTI-TNF PRODUCTS
- L4C INTERLEUKIN INHIBITORS
- Ixekizumab, ustekinumab, secukinumab, and risankizumab when indicated for psoriasis alone are classified in D5B.
 - Anakinra and sarilumab are classified in M1C.
 - Daclizumab when indicated for use in kidney transplantation is classified here. Daclizumab for multiple sclerosis and other conditions is classified in N7A.
 - Dupilumab for atopic dermatitis is classified in D5X.
 - Dupilumab when also indicated for asthma is classified here.
 - Tildrakizumab is classified in D5B.

WHO (Substance Based)

- L04A D Calcineurin inhibitors ❖
- L04A X Other immunosuppressants L4X
- Methotrexate is classified in L01B and L04A X.
 - Lenalidomide, pomalidomide, and thalidomide are classified here.
 - Dimethyl fumarate is classified here.
 - Ruxolitinib is classified in L01X E.
 - Darvadstrocel is classified here.

EphMRA (Product Based)

- Calcineurin inhibitors when indicated for prevention of organ rejection are classified in L4X.
- OTHER IMMUNOSUPPRESSANTS
- Methotrexate is classified in D5B, M1C and L01B.
 - Lenalidomide, pomalidomide, and thalidomide for multiple myeloma (MM) are classified in L1X2. Thalidomide, when used for erythema nodosum leprosum (ENL) only is classified here; when indicated for MM and ENL it is classified in L1X2.
 - Dimethyl fumarate when indicated for multiple sclerosis is classified in N7A; when indicated for psoriasis it is classified in D5B.
 - Ruxolitinib is classified in L1H9.
 - Darvadstrocel is classified in A7E9.

-
- M MUSCULO-SKELETAL SYSTEM**
- M01 ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS**
- M01A ANTIINFLAMMATORY and ANTIRHEUMATIC PRODUCTS, NON STEROIDS
- This group comprises antiinflammatory preparations for systemic use, regardless of strength.
 - Mefenamic acid is classified here.
 - Ketorolac is classified here.
 - Chondroitin, Diacerein and Glucosamine are classified here.

-
- M MUSCULO-SKELETAL SYSTEM**
- M1 ANTIINFLAMMATORY AND ANTI-RHEUMATIC PRODUCTS**
- M1A ANTI-RHEUMATIC, NON STEROIDAL
- Anti-inflammatory analgesics used for both musculo-skeletal conditions and analgesia are classified in M1A. Those that are indicated mainly for general pains are in N2B.
 - Mefenamic acid is classified in N2B.
 - Ketorolac is classified in N2B.
 - Chondroitin, Diacerein and Glucosamine are classified in M5X.

WHO (Substance Based)

- M01B ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION
- M01B A Antiinflammatory/antirheumatic agents in combination with corticosteroids

- M01C SPECIFIC ANTIRHEUMATIC AGENTS
- Chloroquine is classified in P01B.
 - Anakinra, sarilumab, abatacept, tofacitinib, leflunomide, baricitinib, and tocilizumab are classified in L04A.
 - Methotrexate is classified in L01B and L04A.
 - Upadacitinib is classified in L04A

- M02 TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
- M02A TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
- Bendazac is classified here.
 - Bufexamac is classified here.
 - Chymotrypsin is classified in B06A A when used as haematological enzymes.
 - Tolperisone is classified here.

EphMRA (Product Based)

- M1B ANTI-RHEUMATIC CORTICOSTEROID COMBINATIONS

- M1C SPECIFIC ANTI-RHEUMATIC AGENTS
- Chloroquine is classified here and in P1D.
 - Anakinra, sarilumab, abatacept, baricitinib, and tocilizumab are classified here.
 - Tofacitinib and leflunomide when indicated for multiple conditions are classified in L4X.
 - Methotrexate is classified in D5B, M1C and L01B.
 - Upadacitinib is classified here.

- M2 TOPICAL ANTI-RHEUMATICS AND ANALGESICS
- M2A TOPICAL ANTI-RHEUMATICS AND ANALGESICS
- Bendazac is classified in D3A.
 - Bufexamac is also classified in D4A.
 - Nimesulide in throat preparations is also classified in R2A.
 - Chymotrypsin is classified here or in A9A, C5B, D3A and V3H depending on indications.
 - Tolperisone is classified in M3B.

WHO (Substance Based)

M03	MUSCLE RELAXANTS
M03A	MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS ➤ Dantrolene is classified in M03C.
M03B	MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
M03C	MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS ➤ Dantrolene is classified here.

M04	ANTI-GOUT PREPARATIONS
M04A	ANTI-GOUT PREPARATIONS

M5	DRUGS FOR TREATMENT OF BONE DISEASES
M05B	DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION ➤ Eptotermin alfa is classified here. ➤ Dibotermin alfa is classified here. ➤ Burosumab is classified here.

EphMRA (Product Based)

M3	MUSCLE RELAXANTS
M3A	MUSCLE RELAXANTS, PERIPHERALLY ACTING ➤ Dantrolene is classified here.
M3B	MUSCLE RELAXANTS, CENTRALLY ACTING Tolperisone is classified here.
❖	➤ Dantrolene is classified in M3A.

M4	ANTI-GOUT PREPARATIONS
M4A	ANTI-GOUT PREPARATIONS

M5	OTHER DRUGS FOR DISORDERS OF THE MUSCULOSKELETAL SYSTEM
M5B	BONE CALCIUM REGULATORS ➤ Eptotermin alfa is classified in M5X. ➤ Dibotermin alfa is classified in M5X. ➤ Burosumab is classified in M5X.

WHO (Substance Based)

- M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULOSKELETAL SYSTEM
- M09A OTHER DRUGS FOR DISORDERS OF THE MUSCULOSKELETAL SYSTEM
- M09A A Quinine and DERIVATES
- +**
- M09A X Other drugs for disorders of the Musculo-skeletal system
- Eptotermin alfa is classified in M05B.
 - Dibotermin alfa is classified in M05B.
 - Mexiletine is classified in C01B.
- M09A B Enzymes
- Bromelains is classified in B06A A.
 - Chymotrypsin and trypsin are classified in B06A A when used as haematological enzymes.

-
- N NERVOUS SYSTEM**
- N01 ANESTHETICS**
- N01A ANESTHETICS, GENERAL
- Droperidol is classified in N5A.

EphMRA (Product Based)



Inc in M5X ALL OTHER MUSCULOSKELETAL PRODUCTS

- Eptotermin alfa is classified here.
- Dibotermin alfa is classified here.
- Burosumab is classified here.
- Mexiletine is classified here for non-dystrophic myotonic disorders; when indicated for cardiac arrhythmias it is classified in C1B.

V3H

ANTI INFLAMMATORY ENZYMES

- Bromelains is classified here or, in A9A and D3A depending on indications.
- Chymotrypsin is classified here or in A9A, C5B, D3A and M2A depending on indications.

-
- N CENTRAL NERVOUS SYSTEM**
- N1 ANAESTHETICS**
- N1A ANAESTHETICS, GENERAL

- Phenoperidine and anileridine are classified in N2A.
- Droperidol is classified here or in N2A or N5A.

WHO (Substance Based)

N01B ANESTHETICS, LOCAL
➤ Capsicum for neuropathic pain is classified here, otherwise it is in M02A.

N02 ANALGESICS
➤ All antiinflammatory products are classified in M01A, regardless of strength.
➤ Analgesic/cold preparations are classified here intended for use as pain relief.
➤ Analgesics indicated for dysmenorrhea are classified here.

N02A OPIOIDS
➤ This classification is based solely on substances, not on legal status.
➤ Dihydrocodeine is classified here.
➤ Droperidol is classified in N5A.

N02B OTHER ANALGESICS AND ANTIPYRETICS

N02C ANTIMIGRAINE PREPARATIONS
➤ Dihydroergotamine which is also used in the treatment of hypotension, is classified in this group.
➤ Pizotifen is classified here.

EphMRA (Product Based)

N1B ANAESTHETIC LOCAL
➤ Topical capsicum is classified in M2A or, when used for neuropathic pain, in N7X.

N2 ANALGESICS
➤ Anti-inflammatory analgesics used for both musculo-skeletal conditions and analgesia are classified in M01A. Those that are indicated mainly for general pains are in N2B.
➤ Analgesic/cold preparations are classified in R5A.
➤ Products specifically indicated for dysmenorrhea are classified in G2X1.

N2A NARCOTICS
➤ Includes all analgesics classified as narcotics in accordance with the legal definition of narcotic analgesics in each country.
➤ Dihydrocodeine is classified in N2B.
➤ Droperidol is classified here, or in N1A or N5A.

N2B NON-NARCOTICS AND ANTI-PYRETICS WHY DELETED?

N2C ANTI MIGRAINE PREPARATIONS
➤ Dihydroergotamine is classified here and also in C1C1.
➤ Pizotifen is classified here and in A15.
➤ Lisuride is classified in N4A.

WHO (Substance Based)

- Lisuride (low dose) is classified here and in G02C (high dose).
- Flumedroxone is classified here.
- Indoramin is classified in C02.

EphMRA (Product Based)

- Flumedroxone is classified in G3D.
- Indoramin is classified here and in C2.

N03 ANTIEPILEPTICS

N03A ANTIEPILEPTICS

- Cannabinoids (cannabidiol and tetrahydrocannabinol) are classified here.

N3 ANTI-EPILEPTICS

N3A ANTI-EPILEPTICS

- Cannabinoids (cannabidiol and tetrahydrocannabinol), used for refractory spasticity, are classified in N7X.

N04 ANTI-PARKINSON DRUGS

N04A ANTICHOLINERGIC AGENTS

+

N04B DOPAMINERGIC AGENTS

- Lisuride is classified in N02C and in G02C.

N4 ANTI-PARKINSON DRUGS

- Lisuride is classified here.

N05 PSYCHOLEPTICS

The group is divided into therapeutic subgroups:

N05A – Antipsychotics

➡ N05B – Anxiolytics

➡ N05C – Hypnotics and sedatives

N05A ANTIPSYCHOTICS

- Lithium is classified here.
- Droperidol is classified here.

N5 PSYCHOLEPTICS

The group is divided into therapeutic subgroups:

N5A – Antipsychotics

➡ N5B – Hypnotic/Sedatives

➡ N5C – Tranquilizers

N5A ANTIPSYCHOTICS

- Lithium is classified in N6A.
- Droperidol is classified here, or in N1A or N2A.

WHO (Substance Based)

- N05B ANXIOLYTICS
- Mebutamate is classified here.
 - Mefenoxalone is classified here.

- N05C HYPNOTICS AND SEDATIVES
- Melatonin is classified here.

EphMRA (Product Based)

- N5C TRANQUILLISERS
- Mebutamate is classified in C2A.
 - Metenoxalone is classified in M3B.
 - Mebicar is classified here.
- N5B HYPNOTICS / SEDATIVES
- Melatonin (plain) indicated for sleep rhythm disturbances is classified in H4X. Prolonged-release melatonin indicated for primary insomnia is classified here.

N06 PSYCHOANALEPTICS

- N06A ANTIDEPRESSANTS
- Lithium is classified in N05A.
 - Ademetionine is in A16A.
 - Bupropion is classified here.

N6 PSYCHOANALEPTICS EXCL. ANTI-OBESITY PREPARATIONS

- N6A ANTI-DEPRESSANTS AND MOOD STABILISERS
- Lithium is classified here.
 - Ademetionine is classified here.
 - Bupropion is classified here and in N7B.

- N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
- Dexamfetamine and metamfetamine are classified here.
 - Caffeine is classified here.
 - Citicoline is classified here.
 - Atomoxetine is classified here.
 - Mebicar is classified here.
 - Solriamfetol is classified here.

- N6B PSYCHOSTIMULANTS
- Dexamfetamine and metamfetamine are classified here and in A8.
 - Plain caffeine is classified in C1C1.
- +
- Citicoline is classified in C4A.
 - Mebicar is classified in N5C.
 - Atomoxetine is classified in N7X.
 - Solriamfetol is classified in N7X.

WHO (Substance Based)

EphMRA (Product Based)

		N6D	NOOTROPICS ➤ Citicoline is classified in C4A.
		+	
		N6E	NEUROTONICS AND OTHER MISCELLANEOUS PRODUCTS
N06C	PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION	N6C	PSYCHOLEPTIC-PSYCHOANALEPTIC COMBINATIONS
N06D	ANTI-DEMENTIA DRUGS ➤ Ipidacrine is classified here.	N7D	ANTI-ALZHEIMER PRODUCTS ➤ Ipidacrine is classified in N7X.
N07 ↻	OTHER NERVOUS SYSTEM DRUG	N7	OTHER CNS DRUGS
N07A	PARASYMPATHOMIMETICS ➤ Nalorphine, naltrexone, naloxone and flumazenil are classified in V03A. ➤ Cevimeline is classified here. ➤ Alemtuzumab is classified in L04A A. ➤ Solriamfetol is classified in N06B.	❖ Inc in N7X	OTHER CNS DRUGS ➤ Nalorphine, naltrexone, naloxone, flumazenil, and ipidacrine are classified in N7X. ➤ Cevimeline is classified in A01A. ➤ Alemtuzumab when indicated for multiple sclerosis is classified here. ➤ Solriamfetol is classified here.
N07B	DRUGS USED IN ADDICTIVE DISORDERS		
N07B A	Drugs used in nicotine dependence ➤ Bupropion is classified in N6A.	N7B	ANTISMOKING PRODUCTS ➤ Bupropion is classified here and in N6A (antidepressant).

WHO (Substance Based)

N07B B Drugs used in alcohol dependence

- Nalmefene is classified here.

N07B C Drugs used in opioid dependence

N07C ANTIVERTIGO PREPARATIONS



- Natalizumab and ocrelizumab are classified in L04AA.
- Alemtuzumab, fingolimod, siponimod, and terflunomide are classified in L04AA.
- Daclizumab is classified in L04A C.
- All forms of biotin are classified in A11H A.
- Cladribine when indicated for multiple sclerosis is classified in L04A.

EphMRA (Product Based)

N7E DRUGS USED IN ALCOHOL DEPENDENCE

- Nalmefene is also classified in N7X.

N7F DRUGS USED IN OPIOID DEPENDENCE

N7C ANTIVERTIGO PREPARATIONS

N7A MULTIPLE SCLEROSIS PRODUCTS

- Natalizumab and ocrelizumab are classified here.
- Daclizumab is classified here, except when indicated for kidney transplantation when it is classified in L4C.
- Alemtuzumab, dimethyl fumarate, fingolimod, siponimod, glatiramer acetate, laquinimod, terflunomide, etc when indicated for multiple sclerosis are classified here.
- Beta interferons indicated for multiple sclerosis only are classified here.
- High-dose single-ingredient biotin indicated for multiple sclerosis only is classified in N7A.
- Fampridine is classified in N7X.
- Dimethyl fumarate when indicated for multiple sclerosis is classified here.
- Cladribine when indicated for multiple sclerosis is classified here.

WHO (Substance Based)

N07X

OTHER NERVOUS SYSTEM DRUGS



- Sugammadex is classified in V03A B here.
- Topical capsicum, when used for neuropathic pain, is classified in N01B.
- Cannabinoids (cannabidiol and tetrahydrocannabinol) are classified in N03A.
- Tafamidis is classified here.

EphMRA (Product Based)

N7X

ALL OTHER CNS DRUGS

- Sugammadex is classified here.
- Topical capsicum, when used for neuropathic pain, is classified here.
- Cannabinoids (cannabidiol and tetrahydrocannabinol) are classified here.
- Ipidacrine is classified here.
- Nalmefene is also classified in N7E.
- Pilocarpine when indicated for dry mouth and dry eye are classified here.
- Tafamidis for transthyretin amyloid cardiomyopathy only is classified in C1X; otherwise it is classified here.

P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS

This group is subdivided according to types of parasites

P01 ANTIPROTOZOALS



P01A AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES

- Systemic metronidazole is classified here and in J01X D.
- Clioquinol, chlorquinaldol, tilbroquinol and glycobarsol are classified here.

P PARASITOLOGY

P1 ANTI-PARASITIC PRODUCTS



P1A AMOEBICIDES

- Nitroimidazole derivatives are classified either in G1A or J8B.
- Clioquinol, chlorquinaldol, tribroquinol and glycobarsol are classified in A7A.

WHO (Substance Based)

P01B ANTI-MALARIALS
 ➤ Chloroquine and hydroxychloroquine are classified here.

P01C AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS
 ➔ ➤ Miltefosine is classified here.

P02 ANTHELMINTICS
 ➔

The anthelmintics are subdivided according to the main type of worms (i.e. trematodes, nematodes and cestodes) causing the infections.

- Levamisole is classified here.
- Ivermectin is classified in here and in D11A.
- Miltefosine is classified in P01C.

P03 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTISIDES AND REPELLENTS

P03A ECTOPARASITICIDES, INCL. SCABICIDES
 • Ivermectin is classified in P02C and D11A.

EphMRA (Product Based)

P1D ANTI-MALARIALS
 ➤ Chloroquine and hydroxychloroquine are classified here and in M1C.

P1G OTHER ANTI-PARASITIC AGENTS
 ➤ Miltefosine is classified here when indicated for treatment of leishmaniasis and free-living amoeba. It is classified in L1X9 for oncology indications.

P1C SCHISTOSOMICIDES

➔

+

P1B ANTHELMINTICS, EXCL. SCHISTOSOMICIDES

- Levamisole is classified here in L3A.
- Ivermectin is classified here and in P3A, depending on indication.

P3 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTISIDES AND REPELLENTS

P3A ECTOPARASITICIDES, incl. SCABICIDES
 ➤ Ivermectin is classified here and in P1B, depending on indication.

WHO (Substance Based)

P03B INSECTICIDES AND REPELLENTS
➤ Dimethylphthalate is classified here.

R RESPIRATORY SYSTEM

R01 NASAL PREPARATIONS

R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE

R01B NASAL DECONGESTANTS FOR SYSTEMIC USE

R02 THROAT PREPARATIONS

R02A THROAT PREPARATIONS

➤ Preparations for the treatment of throat infections (lozenges for common cold condition) are classified here.

R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES

This group is harmonized on the second level.

➤ Alfa 1 antitrypsin (alpha-1-proteinase inhibitor) is classified in B02A.

➤ Azelastine is classified in R06A.

➤ Ketotifen is classified in R06A.

➤ Terfenadine is classified in R06A.

EphMRA (Product Based)

P3B INSECTICIDES AND REPELLENTS
➤ Dimethylphthalate is classified in D4A.

R RESPIRATORY SYSTEM

R1 NASAL PREPARATIONS

R01A TOPICAL NASAL PREPARATIONS

R1B SYSTEMIC NASAL PREPARATIONS

R2 THROAT PREPARATIONS

R2A THROAT PREPARATIONS

➤ Products indicated for both the posterior part of the mouth and throat infections are classified in R2A or A1A depending on the main indication.

➤ Nimesulide in throat preparations is also here.

R3 ANTI-ASTHMA AND COPD PRODUCTS

➤ Alpha-1-proteinase inhibitor (alfa 1 antitrypsin) is classified here.

➤ Azelastine is classified here.

➤ Ketotifen is classified here.

➤ Terfenadine (Japan only) is classified here, in all other countries in R6A.

WHO (Substance Based)

EphMRA (Product Based)

❖		R4	CHEST RUBS AND OTHER INHALANTS
R05	COUGH AND COLD PREPARATIONS	R5	COUGH AND COLD PREPARATIONS
➡	<ul style="list-style-type: none"> ➤ Cold preparations with therapeutic levels of antiinfectives should be classified in ATC group J – Antiinfectives for systemic use. ➤ Cold preparations with therapeutic levels of analgesics/ antiinflammatory agents should be classified in the respective N02/M01 groups. 		<ul style="list-style-type: none"> ➤ COUGH/COLD PREPARATIONS WITH ANTI-INFECTIVES (R5B) ➤ COLD PREPARATIONS WITHOUT ANTI-INFECTIVES (R5A)
R05C	EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS	R5C	EXPECTORANTS
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS	R5D	ANTITUSSIVES
	➤ Cough suppressants with expectorants are in R05F.		➤ Cough suppressants combination preparations are here in R5D2.
+			
R05F	COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS	R5F	OTHER COUGH AND COLD PREPARATIONS
			➤ This group includes combinations without clearly expectorating or antitussive effect, expectorant teas and lozenges / medical sweets for cough.
R05X	OTHER COLD PREPARATIONS	❖	

WHO (Substance Based)

R06 ANTIHISTAMINES FOR SYSTEMIC USE

R06A ANTIHISTAMINES FOR SYSTEMIC USE

- Antihistamines for systemic use are classified here.
- Cyproheptadine is classified here.
- Thiethylperazine is classified here.
- Azelastine and ketotifen are classified here.

R07 OTHER RESPIRATORY SYSTEM PRODUCTS

R07A OTHER RESPIRATORY SYSTEM PRODUCTS

R07A A LUNG SURFACTANTS

R07A B RESPIRATORY STIMULANTS

R07A X OTHER RESPIRATORY SYSTEM PRODUCTS

S SENSORY ORGANS

S01 OPHTHALMOLOGICALS

S01A ANTIINFECTIVES

S01A D Antivirals

S01B ANTIINFLAMMATORY AGENTS

S01B C Antiinflammatory agents, non-steroids

EphMRA (Product Based)

R6 SYSTEMIC ANTIHISTAMINES

R6A SYSTEMIC ANTIHISTAMINES

- Antihistamines used in motion sickness are classified in A4A.
- Cyproheptadine is also classified in A15.
- Thiethylperazine is classified in A4A.
- Azelastine and ketotifen are classified in R3C.

R7 OTHER RESPIRATORY SYSTEM PRODUCTS

R7C LUNG SURFACTANTS

R7A RESPIRATORY STIMULANTS

R7X ALL OTHER RESPIRATORY SYSTEM PRODUCTS

S SENSORY ORGANS

S1 OPHTHALMOLOGICALS

S1A OPHTHALMOLOGICAL ANTI-INFECTIVES

+

S1D OPHTHALMOLOGICAL ANTIVIRAL AGENTS

S1B OPHTHALMOLOGICAL CORTICOSTEROIDS

+

S1R OPHTHALMIC NONSTEROIDAL ANTIINFLAMMATORIES

WHO (Substance Based)

EphMRA (Product Based)

S01C ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION

S1C OPHTHALMOLOGICAL ANTI-INFLAMMATORY/ ANTIINFECTIVE COMBINATIONS

S01E ANTIGLAUCOMA PREPARATIONS AND MIOTICS

S1E MIOTICS AND ANTIGLAUCOMA PREPARATIONS

S01F MYDRIATICS AND CYCLOPLEGICS

S1F MYDRIATICS AND CYCLOPLEGICS

S01G DECONGESTANTS AND ANTIALLERGICS

S1G OCULAR ANTI-ALLERGICS, DECONGESTANTS, ANTISEPTICS

S01H LOCAL ANESTHETICS

S1H OPHTHALMOLOGICAL LOCAL ANESTHETICS

S01J DIAGNOSTIC AGENTS

S1T OPHTHALMOLOGICAL DIAGNOSTIC AGENTS

S01K SURGICAL AIDS

S1S OPHTHALMOLOGICAL SURGICAL AIDS

S1L ANTINEOVASCULARISATION AGENTS

➤ Aflibercept for macular degeneration is classified here, and for metastatic colorectal cancer in L1X X

S1P OCULAR ANTINEOVASCULARISATION PRODUCTS

• Aflibercept is classified here and in L1X.



S1K ARTIFICIAL TEARS AND OCULAR LUBRICANTS



S1L PREPARATIONS FOR USE WITH CONTACT LENSES

WHO (Substance Based)

EphMRA (Product Based)

❖		S1M	EYE TONICS and EYE VITAMINS
❖		S1N	PREPARATIONS TO PREVENT CATARACT AND ANTICATARACTOGENICS
S01X	OTHER OPHTHALMOLOGICALS	S1X	OTHER OPHTHALMOLOGICALS
S02	OTOLOGICALS	S2	OTOLOGICALS
S02A	ANTIINFECTIVES	S2A	OTIC ANTI-INFECTIVES
S02B	CORTICOSTEROIDS	S2B	OTIC CORTICOSTEROIDS
S02C	CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION	S2C	OTIC CORTICOSTEROID/ANTIINFECTIVE COMBINATIONS
S02D	OTHER OTOLOGICALS	S2D	OTHER OTOLOGICALS
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS	S3	OPHTHALMOLOGICAL/OTOLOGICAL COMBINATIONS
S03A	ANTIINFECTIVES	S3A	EYE/EAR ANTI-INFECTIVES
S03B	CORTICOSTEROIDS	S3B	EYE/EAR CORTICOSTEROIDS

WHO (Substance Based)

S03C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMB.

S03D OTHER OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS

V VARIOUS

V01 ALLERGENS

V01A ALLERGENS

V03 ALL OTHER THERAPEUTIC PRODUCTS

V03A ALL OTHER THERAPEUTIC PRODUCTS

V03A B ANTIDOTES

- Zinc acetate is classified in A16A.
- Sugammadex is classified here.
- Plain phentolamine as an antidote is classified here.
- Idarucizumab and andexanet alfa are classified here.

V03A C IRON CHELATING AGENTS

V03A E DRUGS FOR THE TREATMENT OF HYPERKALEMIA AND HYPERPHOSPHATEMIA

- Colestilan is classified here.

EphMRA (Product Based)

S3C EYE/EAR CORTICOSTEROID/ANTI-INFECTIVE COMBI.

S3D OTHER EYE/EAR COMBINATIONS

V VARIOUS

V1 ALLERGENS

V1A ALLERGENS

V3 ALL OTHER THERAPEUTIC PRODUCTS

V3A ❖

V3E ANTIDOTES

- Zinc acetate is classified here when indicated for Wilson's disease.
- Sugammadex is classified in N7X.
- Phentolamine for erectile dysfunction is in G4E.
- Phentolamine when used as an antidote is classified in V3X.
- Idarucizumab and andexanet alfa are classified in B2B9.

V3F IRON-CHELATING AGENTS

V3G HYPERKALAEMIA/HYPERPHOSPHATEMIA PRODUCTS

- Colestilan is also classified in C10A.

WHO (Substance Based)

- Calcium acetate is classified here.
- Other plain calcium products are classified in A12A.

V03A F DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT

V03A G –

V03A Z ➤ Nalfurafine is classified in V03A X.

- Phentolamine when used as an antidote/reversal agent is classified in V03A B.

- Trypsin is classified in B06A A when used as haematological enzymes.

- Cobicistat is classified in V03AX.

EphMRA (Product Based)

- Calcium-containing products indicated for hyperphosphatemia and calcium deficiency are classified here.

V3D

DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT

V3X

ALL OTHER THERAPEUTIC PRODUCTS

- Nalfurafine is classified in D4A.

- Phentolamine when used as an antidote is classified here.

- Trypsin is classified here or in A9A and V3H depending on indications.

- Cobicistat is classified in J5C9.

V04 DIAGNOSTIC AGENTS



T

DIAGNOSTIC AGENTS

V04B URINE TESTS

T2C

PREGNANCY AND OVULATION TESTS

T2D1

Diabetes tests, urine

T2X1

All other diagnostic tests, urine

V04C OTHER DIAGNOSTIC AGENTS

T2X2 +

All other diagnostic tests, blood

T2X9

All other diagnostic tests

WHO (Substance Based)

V04C A Tests for diabetes



V06 GENERAL NUTRIENTS

V06A DIET FORMULATIONS FOR TREATMENT OF OBESITY

V06B PROTEIN SUPPLEMENTS

V06C INFANT FORMULAS

V06D OTHER NUTRIENTS

V07 ALL OTHER NON-THERAPEUTIC PRODUCTS

V07A ALL OTHER NON-THERAPEUTIC PRODUCTS

V08 CONTRAST MEDIA

V08A X-RAY CONTRAST MEDIA, IODINATED

V08B X.RAY CONTRAST MEDIA, NON-IODINATED

EphMRA (Product Based)

T2D2 + Diabetes tests, blood

T2D9 Diabetes tests, other

T3 DIAGNOSTIC EQUIPMENT AND ACCESSORIES

V6 DIETETIC AGENTS

V6A SLIMMING PREPARATIONS

V6B PROTEIN SUPPLEMENTS

V6C INFANT FORMULAS

V6D OTHER NUTRIENTS

V7 ALL OTHER NON-THERAPEUTIC PRODUCTS

V7A ALL OTHER NON-THERAPEUTIC PRODUCTS



Classified in group T

T1A + LOW OSMOLAR ANGIO-UROGRAPHY

T1B + IONIC ANGIO-UROGRAPHY

T1D CHOLECYSTOGRAPHY AND CHOLANGIOGRAPHY

T1C GASTROENTEROGRAPHY

WHO (Substance Based)

V08C MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
V08D ULTRASOUND CONTRAST MEDIA

EphMRA (Product Based)

T1E MRI AGENTS
❖
T1F ULTRASOUND AGENTS
T1X OTHER IMAGING AGENTS

V09 DIAGNOSTIC RADIOPHARMACEUTICALS

❖ Classified in group T
T1G RADIODIAGNOSTIC AGENTS

V10 THERAPEUTIC RADIOPHARMACEUTICALS

V3C RADIOPHARMACEUTICALS

➤ Ibritumomab tiuxetan, tositumomab and iodine (131I) tositumomab are classified here.

➤ Ibritumomab tiuxetan, tositumomab and iodine (131I) tositumomab are classified in L1G.

V20 SURGICAL DRESSINGS

❖
